Citadel Advisors
LSTA icon

Citadel Advisors’s Lisata Therapeutics LSTA Stock Holding History

Citadel Advisors’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,093
Closed -$12K – 13596
2022
Q1 		$12K Sell
1,093
-534
-33% -$6.11K ﹤0.01% 13357
2021
Q4 		$21K Sell
1,627
-3,266
-67% -$50.4K ﹤0.01% 13577
2021
Q3 		$90K Sell
4,893
-727
-13% -$14.3K ﹤0.01% 12978
2021
Q2 		$136K Buy
5,620
+473
+9% +$11.2K ﹤0.01% 12605
2021
Q1 		$149K Buy
5,147
+2,720
+112% +$82.4K ﹤0.01% 12041
2020
Q4 		$52K Sell
2,427
-1,940
-44% -$46K ﹤0.01% 10552
2020
Q3 		$118K Buy
4,367
+2,760
+172% +$87.3K ﹤0.01% 9171
2020
Q2 		$43K Buy
+1,607
New +$47.3K ﹤0.01% 9365
2015
Q3 		– Sell
-31
Closed -$9K – 9081
2015
Q2 		$9K Buy
31
+2
+7% +$743 ﹤0.01% 8438
2015
Q1 		$11K Sell
29
-5
-15% -$2.71K ﹤0.01% 8171
2014
Q4 		$19K Sell
34
-6
-15% -$4.08K ﹤0.01% 7847
2014
Q3 		$33K Sell
40
-11
-22% -$9.63K ﹤0.01% 7156
2014
Q2 		$50K Buy
51
+33
+183% +$32.1K ﹤0.01% 6740
2014
Q1 		$19K Buy
+18
New +$19.5K ﹤0.01% 7311

Other funds holding LSTA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $639M AUM 31.05% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Citadel Advisors's LSTA Position: Q1 2026 in Review

Citadel Advisors opened a new position in Lisata Therapeutics (LSTA) in Q1 2026: 22,666 shares worth $114K. The stake represents ﹤0.01% of the portfolio and ranks #11900 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in LSTA as recently as Q4 2024.

Citadel Advisors first reported a position in LSTA in Q1 2014 and has held it in 18 quarters since. The position peaked at $128K in Q4 2014. 34 funds tracked by Wall St. Rank hold LSTA as of Q1 2026.

  • Citadel Advisors held 22,666 shares of Lisata Therapeutics worth $114K as of Q1 2026.
  • Lisata Therapeutics was a new Citadel Advisors position in Q1 2026.
  • Lisata Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #11900 holding.
  • Citadel Advisors first reported a position in Lisata Therapeutics in Q1 2014 and has held it in 18 quarters since.
  • Citadel Advisors's Lisata Therapeutics position peaked at $128K in Q4 2014.
  • 34 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.